Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention Brookings Institution, the most common co-covered peer. At 8, the average consequence score sits above the same-window beat average of 6.4.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Neal Dunn
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention Brookings Institution, the most common co-covered peer. At 8, the average consequence score sits above the same-window beat average of 6.4. They are better corroborated than the beat average, carrying 3 original sources each against 2.7 for the same window. We currently track 1 Finance story that mention Neal Dunn, all published on March 19, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 105 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Neal Dunn. Shared-story counts are live from our verified record — not editorial picks.
The House Select Committee on China has warned that Beijing is executing a strategic 'playbook' to dominate the global pharmaceutical market, mirroring its previous successes in rare earths and electric vehicles. With Chinese medical revenue projected to reach $2.1 trillion by 2030, US officials are weighing the national security risks of a supply chain heavily dependent on Chinese-made active pharmaceutical ingredients.
Neal Dunn is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
